CA3062233C - Anticorps diriges contre l'antigene carcino-embryonnaire pour la therapie et le diagnostic du cancer - Google Patents

Anticorps diriges contre l'antigene carcino-embryonnaire pour la therapie et le diagnostic du cancer

Info

Publication number
CA3062233C
CA3062233C CA3062233A CA3062233A CA3062233C CA 3062233 C CA3062233 C CA 3062233C CA 3062233 A CA3062233 A CA 3062233A CA 3062233 A CA3062233 A CA 3062233A CA 3062233 C CA3062233 C CA 3062233C
Authority
CA
Canada
Prior art keywords
antibody
cea
iga
seq
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA3062233A
Other languages
English (en)
Other versions
CA3062233A1 (fr
Inventor
Armelle Cuvillier
Gael Champier
Original Assignee
B CELL DESIGN
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP17305498.2A external-priority patent/EP3398967A1/fr
Application filed by B CELL DESIGN filed Critical B CELL DESIGN
Publication of CA3062233A1 publication Critical patent/CA3062233A1/fr
Application granted granted Critical
Publication of CA3062233C publication Critical patent/CA3062233C/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Abstract

L'invention concerne des anticorps contre l'antigène carcino-embryonnaire (CEA) qui ont une activité d'inhibition de la croissance cellulaire directe sur des cellules tumorales exprimant CEA et leur utilisation pour le traitement et le diagnostic du cancer.
CA3062233A 2017-05-04 2018-05-03 Anticorps diriges contre l'antigene carcino-embryonnaire pour la therapie et le diagnostic du cancer Active CA3062233C (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP17305498.2A EP3398967A1 (fr) 2017-05-04 2017-05-04 Anticorps dirigés contre l'antigène carcino-embryonnaire pour le diagnostic et la thérapie du cancer
EP17305498.2 2017-05-04
PCT/EP2018/061385 WO2018202794A1 (fr) 2017-05-04 2018-05-03 Anticorps dirigés contre l'antigène carcino-embryonnaire pour la thérapie et le diagnostic du cancer

Publications (2)

Publication Number Publication Date
CA3062233A1 CA3062233A1 (fr) 2018-11-08
CA3062233C true CA3062233C (fr) 2026-02-03

Family

ID=

Similar Documents

Publication Publication Date Title
US8901278B2 (en) Pharmaceutical antibody compositions with resistance to soluble CEA
US7090844B2 (en) Use of antibodies against the MUC18 antigen
US7067131B2 (en) Methods for using anti-MUC18 antibodies
Lutterbuese et al. Potent control of tumor growth by CEA/CD3-bispecific single-chain antibody constructs that are not competitively inhibited by soluble CEA
US8071730B2 (en) Anti-JAM-A antibodies
EP4159764A1 (fr) Anticorps bispécifique anti-pdl1 × egfr
JP2022514786A (ja) Ｍｕｃ１８に特異的な抗体
WO2023041065A1 (fr) Anticorps ciblant ceacam5/6 humain, procédé de préparation et application
EP4269442A1 (fr) Molécule de liaison à la mésothéline et son utilisation
KR20250042144A (ko) Itga2를 표적으로 하는 항체 및 이를 포함하는 항체-약물 접합체(antibody targeting itga2 and antibody-drug conjugate comprising the same)
EP3619237B1 (fr) Anticorps dirigés contre l'antigène carcino-embryonnaire pour le diagnostic et la thérapie du cancer
CN111108120A (zh) 抗人类血管内皮生长因子受体的抗体及其应用
CN110563842B (zh) 针对程序性死亡配体(pd-l1)的抗体及其应用
CA3062233C (fr) Anticorps diriges contre l'antigene carcino-embryonnaire pour la therapie et le diagnostic du cancer
TWI919340B (zh) 抗體及其應用
CN121219323A (zh) 抗cldn6抗体及其用途
WO2025257185A1 (fr) Anticorps humanisé anti-antigène carcino-embryonnaire humain
CN117430711A (zh) 用于治疗肝细胞性肝癌的双特异性融合蛋白及其应用
HK40105152A (zh) 对muc18特异性的抗体
WO2021170146A1 (fr) Préparation d'un anticorps anti-cd19 de type nouveau et d'une cellule cd19-car-t, et utilisation associée
NZ569144A (en) Pharmaceutical antibody compositions with resistance to soluble CEA - comprising IgG1antibodies that bind to CEA